The Inaugural International Conference on Deficiency of ADA2

On November 11, 2016, physicians and researchers from around the world met in Bethesda, Maryland to discuss the mechanisms, diagnosis, and treatment of Deficiency of ADA2 and to chart a path forward for research. The meeting was moderated by Dan Kastner, Scientific Director of the National Human Genome Research Institute. At the same time, patients and their families gathered to share their experiences living with DADA2, discuss plans to further the work of the DADA2 Foundation, and meet in a final joint session with the medical attendees. 

The scientific planning committee for the conference included:

Dan Kastner, M.D., Ph.D., Scientific Director of the National Human Genome Research Institute and Head of the Inflammatory Disease Section at the National Institutes of Health.

Michael Hershfield, M.D., Professor of Medicine and Biochemistry at Duke University Medical School

Troy Torgerson, M.D., Ph.D., attending physician at Seattle Children's Hospital and Associate Professor of Pediatric Immunology/Rheumatology at the University of Washington School of Medicine

Ivona Aksentijevich, M.D., Staff Scientist in the Inflammatory Disease Section at the National Institutes of Health and President of the International Society of Systemic Auto-Inflammatory Diseases

Marco Gattorno, M.D., Professor of Pediatric Rheumatology at Istituto G. Gaslini, Genoa, Italy, and Vice President and President Elect of the International Society of Systemic Auto-Inflammatory Diseases

Isabelle Meyts, M.D., Ph.D., Professor of Pediatric Immunology at University Hospitals Leuven, Belgium

Susa Benseler, M.D., Ph.D., Deputy Head Research and Section Chief Rheumatology, Department of Paediatrics, Alberta Children's Hospital and Cumming School of Medicine, University of Calgary, Canada

Chip Chambers, M.D., Founder and President of the DADA2 Foundation, former Chief of Endocrine Surgery at the Vanderbilt University Medical Center, and father of two children with DADA2